5

10

What is claimed:

- 1. A method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.
- The method of claim 1, wherein the antibody is a monoclonal antibody.
- 15 3. The method of claim 1, wherein the antibody is selected from the group consisting of PA8 (ATCC Accession No. HB-12605), PA9 (ATCC Accession No. HB-12606), PA10 (ATCC Accession No. HB-12607), PA11 (ATCC Accession No. HB-12608), PA12 (ATCC Accession No. HB-12609), and PA14 (ATCC Accession No. HB-12610).
 - 4. The method of claim 1, wherein the antibody is PA14 (ATCC Accession No. HB-12610).
 - 5. The method of claim 1, wherein the subject's HIV-1 viral load is reduced to 33% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.
 - 6. The method of claim 1, wherein the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.

35

25

30

10

20

25

- 7. The method of claim 1, wherein the reduction of the subject's HIV-1 viral load is sustained for a period of time.
- 5 8. The method of claim 7, wherein the period of time is at least one day.
 - 9. The method of claim 7, wherein the period of time is at least three days.
 - 10. The method of claim 7, wherein the period of time is at least seven days.
- 11. The method of claim 1, wherein the effective amount
 15 of the antibody is between about 1mg and about 50mg
 per kg body weight of the subject.
 - 12. The method of claim 11, wherein the effective amount of the antibody is between about 2mg and about 40mg per kg body weight of the subject.
 - 13. The method of claim 12, wherein the effective amount of the antibody is between about 3mg and about 30mg per kg body weight of the subject.
 - 14. The method of claim 13, wherein the effective amount of the antibody is between about 4mg and about 20mg per kg body weight of the subject.
- 30 15. The method of claim 14, wherein the effective amount of the antibody is between about 5mg and about 10mg per kg body weight of the subject.
- 35 16. The method of claim 1, wherein the antibody is

5

administered at least once per day.

- 17. The method of claim 1, wherein the antibody is administered daily.
- 18. The method of claim 1, wherein the antibody is administered every other day.
- 19. The method of claim 1, wherein the antibody is administered every 6 to 8 days.
 - 20. The method of claim 1, wherein the antibody is administered weekly.
- 15 21. The method of claim 1, wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.
- 20 22. The method of claim 1, wherein the subject is a human being and the antibody is a humanized antibody.